Dingwei Ye

10.1k citations
135 papers · 5.0k · 6 hit papers · h-index 26

Impact in

Papers in

    • Prostate Cancer Treatment and Research 75
    • Prostate Cancer Diagnosis and Treatment 33
    • Renal cell carcinoma treatment 30
    • Cancer Immunotherapy and Biomarkers 14
    • Cancer Treatment and Pharmacology 12

Dingwei Ye

127 papers receiving 5.0k citations

Hit Papers

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial 2023 · 99 citations
990+3+6Years since publication4008001.2k

Peers

Dingwei Ye
Comparison fields: 5 of 90
  • Pulmonary and Respiratory Medicine 3.9k
  • Cancer Research 1.6k
  • Radiology, Nuclear Medicine and Imaging 1.3k
  • Endocrinology, Diabetes and Metabolism 649
  • Oncology 1.1k
Replace Simon Chowdhury with:
Simon Chowdhury United Kingdom
Nobuaki Matsubara Japan
Aude Fléchon France
Evan Y. Yu United States
Susan Feyerabend United Kingdom
Matthew M. Cooney United States
Bernhard J. Eigl Canada
J Horti Hungary
William R. Berry United States
Mohammad Hirmand United States
Dingwei Ye relative to Simon Chowdhury United Kingdom Simon Chowdhury's profile →
Citations per field
00.5×1.5×2.3×
Simon Chowdhury · 1×
Citations per year

Countries citing papers authored by Dingwei Ye

Since Specialization
Citations

This map shows the geographic impact of Dingwei Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dingwei Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dingwei Ye more than expected).

Fields of papers citing papers by Dingwei Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dingwei Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dingwei Ye. The network helps show where Dingwei Ye may publish in the future.

Co-authors

The 25 scholars most cited alongside Dingwei Ye, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dingwei Ye Line = papers co-authored together Dingwei Ye links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 135 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Hit paper breakdown →
20171413
2
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Hit paper breakdown →
2019891
3
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Hit paper breakdown →
2019517
4
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
Hit paper breakdown →
2021285
5 2010262
6
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
Hit paper breakdown →
2016261
7
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Hit paper breakdown →
202399
8 201969
9 202366
10 201356
11 202148
12 200942
13 202238
14 201738
15 201737
16
[Epidemiology of prostate cancer in China: an overview and clinical implication].
201534
17 201431
18 202130
19 201530
20 201530

About Dingwei Ye

Dingwei Ye is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Surgery and Cancer Research, having authored 135 papers that have together received 5.0k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (75 papers), Prostate Cancer Diagnosis and Treatment (33 papers), Renal cell carcinoma treatment (30 papers), Radiopharmaceutical Chemistry and Applications (28 papers), Bladder and Urothelial Cancer Treatments (18 papers), Cancer Immunotherapy and Biomarkers (14 papers), Cancer, Lipids, and Metabolism (13 papers) and Cancer Treatment and Pharmacology (12 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.9k citations), Cancer Research (1.6k citations), Radiology, Nuclear Medicine and Imaging (1.3k citations), Endocrinology, Diabetes and Metabolism (649 citations) and Oncology (1.1k citations). Dingwei Ye has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Kim N., Mustafa Özgüroğlu, Karim Fizazi, Susan Feyerabend, B. Yа. Alekseev, Andrew Protheroe, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n and Peter De Porre. Their work appears in journals such as Journal of Clinical Oncology, Asian Journal of Andrology, The Prostate, British Journal of Urology and Prostate International.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact